Management of Cardiovascular Risks of COVID-19 Patients
10 July 2020
KEY TAKEAWAYS
- COVID-19 is a systemic disease caused by novel corona SARS-CoV2 virus. It causes inflammation, multi organ failure and in many cases cardiac stress and injury
- COVID-19 is associated with abnormal hemotological, inflammatory, thrombotic and cardiac biomarkers
- Abnormal levels of NT-proBNP and hs-Tn do not necessarily reflect Heart Failure and Acute Myocardial Infarction
- Elevation in the cardiac biomarkers might help in clinical decision making including triage and management as well as imaging in COVID-19 patients
This webinar will shed light on how cardiac involvement due to acute myocarditis may occur in patients with COVID-19 without respiratory tract signs and symptoms of infection.
By attending this webinar you will come away with a greater understanding of :
- The potential mechanisms underlying cardiac biomarkers elevation with COVID-19 infections
- What biomarkers should be tested and when for the diagnosis of cardiovascular conditions in COVID-19 patients
- Value of cardiac biomarkers in COVID-19 patient management
